| USGOV-DEPARTMENT-OF-DEFENSE |
USGOV-DEPARTMENT-OF-DEFENSE |
95%
|
USAspending awards from Department of Defense: $368,774 across 6 awards. HT001426PE058 HAEMONETICS CORPORATION PROVIDES THE ARTERIAL AND VENOUS CLOSURE SHEATHS REQUIRED FOR CARDIAC ELECTROPHYSIOLOGY … |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
95%
|
USAspending awards from Department of Health and Human Services: $47,000 across 1 awards. 75N92020P00263 HEMATOLOGY CLINICAL CONSULT COORDINATOR | Qwen corrected direction: Explicit government contra… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $118,717 across 2 awards. 36C25225C0003 HAEMONETIC BAGS FOR BLOOD AND FLUIDS; 36C10X26K0087 EXPRESS REPORT: NX ORDERS PLACED DURING THE MONTH O… |
| USGOV-NATIONAL-AERONAUTICS-AND-SPACE-ADMINISTRAT |
USGOV-NATIONAL-AERONAUTICS-AND-SPACE-ADMINISTRAT |
95%
|
USAspending awards from National Aeronautics and Space Administration: $131,896 across 1 awards. 80NSSC26P0484 PORTABLE BLOOD ANALYZERS | Qwen corrected direction: Explicit government contract awards… |
| CSL-PLASMA |
CSL-PLASMA |
92%
|
The decrease during the nine months ended December 27, 2025, was driven by lower sales volumes in North America, primarily relating to the previously announced customer transition of CSL Plasma |
| EXISTING-SOFTWARE-CUSTOMER |
EXISTING-SOFTWARE-CUSTOMER |
90%
|
upfront revenue recognition on execution of a renegotiated long-term software agreement with an existing software customer in the first quarter of fiscal 2026 |
| ABT |
Abbott Laboratories |
72%
|
gies (“Terumo BCT”) and Fresenius SE & Co. KGaA, in particular, have significant financial and other resources and are strong competitors in a number of our businesses. The following provides an over… |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from HAE graph: gies (“Terumo BCT”) and Fresenius SE & Co. KGaA, in particular, have significant financial and other resources and are … |
| CSLLY |
CSL Limited |
72%
|
Item 13. Certain Relationships and Related Transactions and Director Independence 109 Item 14. Principal Accounting Fees and Services 109 Item 15. Exhibits, Financial Statement Schedules 110 Table of… |
| CSLLY |
CSL Limited |
72%
|
Reciprocal relationship from CSLLY graph: Reciprocal relationship from HAE graph: Reciprocal relationship from CSLLY graph: Reciprocal relationship from HAE graph: Item 13. Certain Relationships and … |
| FSNUY |
Fresenius SE & Co. KGaA |
72%
|
gies (“Terumo BCT”) and Fresenius SE & Co. KGaA, in particular, have significant financial and other resources and are strong competitors in a number of our businesses. The following provides an over… |
| FSNUY |
Fresenius SE & Co. KGaA |
72%
|
Reciprocal relationship from FSNUY graph: Reciprocal relationship from HAE graph: gies (“Terumo BCT”) and Fresenius SE & Co. KGaA, in particular, have significant financial and other resources and ar… |
| BLOOD-MANAGEMENT-TECHNOLOGIES |
BLOOD-MANAGEMENT-TECHNOLOGIES |
62%
|
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. 40 Table of Contents Plasma Plasma revenue increased… |
| CAPITAL-RESOURCES-RESOURCES |
CAPITAL-RESOURCES-RESOURCES |
62%
|
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. 40 Table of Contents Plasma Plasma revenue increased… |
| FRESENIUS-KABI-AG |
FRESENIUS-KABI-AG |
62%
|
Item Original Notional Amount Notional Amount as of December 27, 2025 Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Asset Fair Value (Dollars in Thousands) 1-month US… |
| FRESENIUS-KABI-USA-LLC |
FRESENIUS-KABI-USA-LLC |
62%
|
Item Original Notional Amount Notional Amount as of December 27, 2025 Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Asset Fair Value (Dollars in Thousands) 1-month US… |
| INTERVENTIONAL-TECHNOLOGIES |
INTERVENTIONAL-TECHNOLOGIES |
62%
|
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit. 40 Table of Contents Plasma Plasma revenue increased… |
| IP2IPO-INNOVATIONS-LTD |
IP2IPO-INNOVATIONS-LTD |
62%
|
Item Original Notional Amount Notional Amount as of December 27, 2025 Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Asset Fair Value (Dollars in Thousands) 1-month US… |
| OPSENS-OPSENS-MEDICAL-INC |
OPSENS-OPSENS-MEDICAL-INC |
62%
|
Item Original Notional Amount Notional Amount as of December 27, 2025 Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Asset Fair Value (Dollars in Thousands) 1-month US… |
| SUZHOU-CO-LTD |
SUZHOU-CO-LTD |
62%
|
acquired from HemoAssay Science and Technology (Suzhou) Co. Ltd., a China-incorporated company, and its affiliates (collectively, “HemoAssay”) in fiscal 2021. The impairment charge was the result of … |
| U-S-BANK-TRUST-COMPANY |
U-S-BANK-TRUST-COMPANY |
62%
|
acquired from HemoAssay Science and Technology (Suzhou) Co. Ltd., a China-incorporated company, and its affiliates (collectively, “HemoAssay”) in fiscal 2021. The impairment charge was the result of … |
| VASCULAR-CLOSURE-SENSOR-GUIDED-TECHNOLOGIES |
VASCULAR-CLOSURE-SENSOR-GUIDED-TECHNOLOGIES |
62%
|
easure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.” (2) Interventional Technologies includes Vasc… |
| VIVASURE-MEDICAL-LIMITED |
VIVASURE-MEDICAL-LIMITED |
62%
|
e fiscal year ended March 29, 2025. The following discussion may contain forward-looking statements and should be read in conjunction with the “Cautionary Statement Regarding Forward-Looking Informat… |
